Finally, Palbociclib and Vemurafenib were tested in an open-label Phase I-II trial involving patients with stage IIIC or IV BRAF-V600E/K mutant metastatic melanoma harboring CDKN2A loss and wild type-RB1-expression. Here, CDKN2A is linked to metastatic melanoma.